Commentary: optimal adjuvant endocrine therapy of postmenopausal breast cancer.
نویسندگان
چکیده
There is a growing body of evidence that the optimal adjuvant endocrine therapy for hormone-sensitive breast cancer in postmenopausal women should include an aromatase inhibitor. However, further research is required to establish the optimal aromatase inhibitor and whether such a drug should be used as monotherapy or in sequence after 2 to 3 years of tamoxifen.
منابع مشابه
Optimizing Endocrine Therapy for Breast Cancer: 'Miles to Go'
The majority of invasive breast cancer patients present with hormone receptor-positive disease, and modulation of estrogen receptor (ER) activation is an essential component of systemic adjuvant therapy for these women. While tamoxifen has traditionally been the primary adjuvant endocrine therapy for all ER-positive women, recent trials evaluating the use of aromatase inhibitors (AIs) have chal...
متن کاملOptimizing endocrine therapy for premenopausal and postmenopausal women with breast cancer.
The majority of invasive breast cancer patients present with hormone receptor-positive disease, and modulation of estrogen receptor (ER) activation is an essential component of systemic adjuvant therapy for these women. While tamoxifen has traditionally been the primary adjuvant endocrine therapy for all ER-positive women, recent trials evaluating the use of aromatase inhibitors (AIs) have chal...
متن کامل[Adjuvant chemotherapy of early stage breast cancer].
UNLABELLED Adjuvant systemic therapy reduces the likelihood of both local and distant relapses by eradicating micrometastases. AIM To survey the adjuvant treatment of early breast cancer. METHODS Author presents an overview of the systemic therapy of early breast cancer based on relevant literature and own experiences. RESULTS Three systemic treatment modalities are widely used as adjuvan...
متن کاملAdjuvant endocrine therapy for breast cancer.
Endocrine therapy is a critical part of adjuvant therapy in women with hormone receptor-positive breast cancer, and has been shown to reduce the risk of recurrence and death from breast cancer. For decades, 5 years of tamoxifen has been the standard treatment. For premenopausal women, it remains so, and we await the results of ongoing trials to define the role of ovarian suppression or ablation...
متن کاملDefining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer.
BACKGROUND Over the past few years, data have been published concerning the relative efficacy and safety profiles of tamoxifen and the aromatase inhibitors (AIs) in the adjuvant therapy setting for women with early hormone receptor-positive breast cancer. Recently, debate has centred around trials which have studied primary tamoxifen and AI therapy, switching and sequencing strategies and exten...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- International journal of fertility and women's medicine
دوره 50 5 Pt 1 شماره
صفحات -
تاریخ انتشار 2005